Larimar Therapeutics (LRMR) Net Income towards Common Stockholders (2016 - 2020)
Historic Net Income towards Common Stockholders for Larimar Therapeutics (LRMR) over the last 8 years, with Q1 2020 value amounting to -$3.6 million.
- Larimar Therapeutics' Net Income towards Common Stockholders rose 7254.66% to -$3.6 million in Q1 2020 from the same period last year, while for Dec 2020 it was -$3.6 million, marking a year-over-year increase of 9206.27%. This contributed to the annual value of -$45.4 million for FY2019, which is 21181.19% down from last year.
- Per Larimar Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$3.6 million for Q1 2020, which was up 7254.66% from -$7.3 million recorded in Q4 2019.
- Larimar Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$3.6 million for Q1 2020, and its period low was -$17.7 million during Q1 2016.
- Its 5-year average for Net Income towards Common Stockholders is -$13.0 million, with a median of -$13.1 million in 2019.
- In the last 5 years, Larimar Therapeutics' Net Income towards Common Stockholders crashed by 3165.08% in 2016 and then skyrocketed by 7254.66% in 2020.
- Larimar Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$10.4 million in 2016, then decreased by 25.35% to -$13.1 million in 2017, then decreased by 11.35% to -$14.6 million in 2018, then skyrocketed by 49.84% to -$7.3 million in 2019, then skyrocketed by 50.66% to -$3.6 million in 2020.
- Its Net Income towards Common Stockholders stands at -$3.6 million for Q1 2020, versus -$7.3 million for Q4 2019 and -$12.9 million for Q3 2019.